Clinical management of aplastic anemia. | Aplastic Anemia and MDS International Foundation

Clinical management of aplastic anemia.

Journal Title: 
Expert Rev Hematol
Author(s): 
Dezern AE, Brodsky RA.
Primary Author: 
Dezern AE
Original Publication Date: 
Friday, April 1, 2011

Abstract

Acquired aplastic anemia is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow. Hematopoietic stem-cell transplantation or bone marrow transplantation (BMT) is the treatment of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and cyclosporine or high-dose cyclophosphamide is an effective therapy for patients who are not suitable BMT candidates owing to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment option is best reserved for those patients who do not respond, relapse or develop secondary clonal disorders following immunosuppressive therapy. Efforts are currently underway to both improve immunosuppressive regimens and to expand the application of BMT.

Bone Marrow Diseases: